AI technology diagnoses cancer with nearly 100% accuracy without a doctor

Experts from the Korea Advanced Institute of Science and Technology (KAIST) have just announced success in developing artificial intelligence (AI) technology for cancer diagnosis and treatment.

The platform, called Lunit Insight, was developed with the ability to diagnose lung and breast cancer - the two most common cancers today, and has shown impressive results with an accuracy of up to 97-99% without the intervention of a radiologist.

In parallel, the Lunit Scope platform is designed to predict patient response to different cancer treatments.

As of the end of July 2025, this technology has been deployed in more than 10,000 medical facilities in 65 countries.

Notably, Lunit has established a strategic partnership with Microsoft to develop a next-generation diagnostic platform, and expanded its market to the Middle East and Europe through a partnership with Volpara Healthcare, a global breast cancer screening specialist.

Lunit founder and chairman Baek Seung Wook stressed that the ultimate goal is to defeat cancer. According to him, early detection not only improves the cure rate but also helps optimize treatment costs through personalized treatments.

Lunit is now expanding its scope from diagnostics to therapeutics, with partnerships with 15 of the world's top 20 pharmaceutical companies, including AstraZeneca and Genentech.

The AI biomarker solution "Lunit Scope" is being developed to improve treatment efficiency by determining patient suitability for specific treatments.